Start-Ups and Spin-Offs in Biotechnology Sector in Poland: Business Models Analysis

Start-Ups and Spin-Offs in Biotechnology Sector in Poland: Business Models Analysis

Anna Białek-Jaworska, Renata Gabryelczyk
Copyright: © 2019 |Pages: 29
DOI: 10.4018/978-1-5225-8903-7.ch053
OnDemand:
(Individual Chapters)
Available
$37.50
Current Special Offers
No Current Special Offers
TOTAL SAVINGS: $37.50

Abstract

This chapter concerns the subject of research-developmental activity of biotech spin-offs in Poland with particular reference to their strategy, determinants of their development and determinants of their financial standing. In the chapter, the authors analyse the determinants of biotech spin-offs and start-ups development in Poland in the light of the research commercialisation cooperation on the universities-business line. The literature overview contains the definition of a process for the commercialisation of the results of research and development (R&D) activity and components of companies' business models. The chapter defines key activities in the development of business models in the context of the commercialisation process and the life cycle of the company, especially at the start up and early stage. Quality-quantitative analysis includes the business models of seven biotechnology spin-offs traded on the alternative market of the Warsaw Stock Exchange, especially the structure of their intellectual capital, R&D expenses in relation to received subsides and grants, third-party shares in start up equity, and the ability to realise the “Go Global” strategy.
Chapter Preview
Top

Determinants Of Biotech Spin-Offs And Start-Ups Development In Poland In The Light Of Research Commercialisation

The research potential in the field of biotechnology and pharmacy in Poland constitutes more than 2,800 scientists specialising in life and medical sciences and working at universities and research institutes, as well as over 8,000 biotechnology students attending 50 higher education institutions where biotechnology is offered as a path of specialisation (93 faculties). More than 100 institutions of science are involved in biotechnology and pharmaceutical R&D projects. Most of the ongoing R&D projects in Poland, including more than 70% of all biotech projects have been initiated with the purpose of developing innovative products (Poland Biotech & Pharma, 2012; GUS, 2013). Poland is ranked 10th worldwide in terms of the number of centres carrying out clinical trials and 1st among the so-called rising markets (1.6% of the global involvement). The Polish market of clinical trials is the largest such market in Central and Eastern Europe. The large number of patients, relatively low operational costs, cost-effective manufacturing, highly skilled workforce, significant know-how in the area of generic medicine advancement, as well as growing experience and high potential in clinical research projects, make Poland an attractive location for clinical research and R&D projects (Go Global! Polish Pharma, 2012).

Complete Chapter List

Search this Book:
Reset